Ra Pharmaceuticals

Biotech

UCB races to regulators after $2B rare disease bet delivers data

With the rare disease clinical trial hitting its primary endpoint, UCB is preparing to file to join AstraZeneca and argenx in a congested space.

Nick Paul Taylor Feb 4, 2022 8:25am

A sheet of paper reading venture capital

Ex-Ra Pharma execs snag $75M for Curie's radiopharmaceuticals

Dec 1, 2021 9:45am

People shaking hands across a desk that has computer and papers on it

UCB strikes $2.5B deal to buy Ra for rival to Alexion's Soliris

Oct 10, 2019 7:35am

Wall Street

IPOs: Ra Pharma raises $92M, as Pfizer to gain rights to Myovant

Oct 26, 2016 9:43am

Nasdaq screens

A pair of biotech IPOs line up: Myovant and Ra Pharma

Oct 3, 2016 10:59am